Inhaled Drug Reduced Pulmonary Hypertension Resistance
A new treatment showed promising improvements for adults living with lung disease-related pulmonary hypertension.
Updated on Sept. 21, 2026 in Heart Disease
Live Poll
Do you feel optimistic about the pace of new treatment options for chronic lung conditions?
The PHocus phase 2 clinical study found that daily inhaled mosliciguat significantly lowered pulmonary vascular resistance in adults with pulmonary hypertension associated with interstitial lung disease (PH-ILD). The results mark a potential shift for a condition that currently has few approved therapy options.
Why it matters
Pulmonary hypertension associated with interstitial lung disease is difficult to manage because limited treatment options exist. This research offers a potential new path for reducing vascular resistance and improving exercise capacity for patients managing this complex condition.
In a Phase 2 trial of 135 adults, those taking inhaled mosliciguat experienced a 51.3% reduction in pulmonary vascular resistance at 16 weeks compared to a 6.6% increase for the placebo group. Researchers also observed a 20.3-meter improvement in the 6-minute walk test and a 53.2% reduction in NT-proBNP levels.
The details
Mosliciguat is an inhaled medication designed to target the soluble guanylate cyclase (sGC) enzyme. By binding directly to the enzyme, the drug facilitates local pulmonary vasodilation, which helps to minimize the exposure of the rest of the body to the medication. This localized delivery approach aims to manage high blood pressure in the lung arteries while reducing potential systemic side effects.
Timeline
16 weeks marked the primary outcome measurement for pulmonary vascular resistance.
24 weeks marked the completion of the daily medication or placebo regimen.
September 21, 2026, saw the presentation of these study results at the ERS International Congress.
Health Landscape
This development addresses a significant gap in treatment for pulmonary hypertension secondary to interstitial lung disease. It builds upon existing research into sGC stimulators while aiming to refine delivery through targeted, local pulmonary administration.
If you are currently managing pulmonary hypertension associated with interstitial lung disease, the results of this trial underscore the importance of discussing emerging treatment options with your physician. Since this drug is still in clinical testing, patients should follow their current care plans while staying informed about future trial developments.
The takeaway
This study indicates that targeted, inhaled therapy may provide a new way to reduce pulmonary vascular resistance in those with lung-related hypertension. Patients should continue monitoring their symptoms and discuss the evolving treatment landscape with a pulmonary specialist.
What happens next
The PHrontier phase 3 trial is currently underway to further evaluate the efficacy and long-term safety of mosliciguat.
Further reading
Learn more about the latest research and management strategies for this condition in our Heart Disease section.
Live Poll
Do you feel optimistic about the pace of new treatment options for chronic lung conditions?
